GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered imaging technologies, radiopharmaceuticals, cyclotrons, chemistry systems, and workflow-optimizing software—designed to support personalized, data-driven care across the entire patient journey. At #SNMMI25, the company is proud to introduce LesionID™ Pro with automated zero-click pre-processing,i which aims to help physicians minimize manual segmentation required to access patient-specific insights that can play a key role in delivering precision care with confidence. At this year's Society of Nuclear Medicine and Molecular Imaging

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- Equity Insider News Commentary – Amid the wave of new AI-powered innovations in healthcare, so far ambient scribes have emerged as the breakout use case. As the range of AI uses for the healthcare sector continues to grow, experts are analyzing the potential ROI on their implementation, and how much they'll benefit early adopters. Healthcare leaders are already seeing improvements, such as slashed clinician workloads from voice AI, and the adoption of AI agents to increase efficiency and smarter care delivery. For investors looking for remaining early-mover advantages, ther

GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT) technology for new clinical pathways to help improve patient outcomes. Total body PET/CT technologyi is designed with the goal of supporting personalized medicine practices like theranostics, improve healthcare system efficiency, and provide scalable solutions for imaging practices and healthcare facilities. Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total b

GE HealthCare expands precision care capabilities with its first combined software release with MIM Encore™, helping enhance digital imaging and workflow solutions across oncology, cardiology, and neurology. The software solution was designed to help tackle key healthcare challenges like improving efficiency, streamlining cross-departmental communication, and reducing manual workloads. Now powered with additional GE HealthCare features and algorithms, MIM Encore delivers an integrated and excellent reporting experience for both PET and SPECT imaging. GE HealthCare (NASDAQ:GEHC) proudly announces the combination of GE HealthCare's proprietary features and algorithms with MIM Encore

BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better clinical decision-making and broader insurance coverage for breast cancer patients. GE HealthCare's Cerianna (fluoroestradiol F18) injection is the first and only U.S. Food and Drug Administration (FDA) approved imaging agent to help clinicians assess estrogen receptor positive (ER+) lesion status in recurrent or metastatic breast cancer. GE HealthCare (NASDAQ:GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for clinicians now recommend considerin

CleaRecon DL receives 510(k) clearance and CE mark, paving the way for clinicians to use 3D image guidance technologies to their full potential with the goal of achieving better clinical and operational outcomes AI-driven solution advances image quality and improves clinical confidence, encouraging adoption of cone-beam computed tomography GE HealthCare (NASDAQ:GEHC) today announced the launch of CleaRecon DL, technology powered by a deep-learning algorithm, to improve the quality of cone-beam computed tomography (CBCT) images. This artificial intelligence (AI)-driven solution is designed to remove streak artifacts caused by the pulsatile nature of blood flow in the arteries and change

The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound enhancing agent available in the U.S. GE HealthCare (NASDAQ:GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company's Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent (UEA). This approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart ab

The companies plan to co-develop solutions that support the integration of Raydiant Oximetry's fetal pulse oximetry technology into GE HealthCare's fetal monitoring and digital perinatal surveillance platforms that have a 60-year history of innovation and industry firsts. Fetal pulse oximetry technology aims to provide real-time insights to clinicians during labor and delivery and improve the detection of fetal distress, potentially reducing newborn neurological injuries, emergency cesarean sections and improving healthcare costs. Expanding fetal monitoring to include oxygen saturation could support clinicians in improving the standard of care by providing a more comprehensive view of

SIGNA™ Sprint, a new wide bore 1.5T MRI scanner, is designed to provide power previously unattainable at 1.5T, for clarity in cardiology and oncology imaging Advanced high-performance gradient technology leverages built-in AI solutions designed to enable clear, fast imaging for improved workflow GE HealthCare (NASDAQ:GEHC) today unveiled SIGNA™ Sprint, an FDA 510(k) pending1 ultra-premium wide bore 1.5T high-performance gradient MRI system, at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025. This innovative technology is designed to unlock advanced imaging possibilities in cardiology, oncology and other clinical and research areas. The need for advanced diagn

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

SD - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He

GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than

Fourth Quarter 2024 Revenue growth was 2% year-over-year; Organic revenue growth* was 2% Net income margin was 13.5% versus 7.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 18.7% versus 16.1% Diluted earnings per share (EPS) were $1.57 versus $0.88 for the prior year; Adjusted EPS* was $1.45 versus $1.18 Cash flow from operating activities was $913 million versus $1.1 billion for the prior year; Free cash flow* was $811 million versus $956 million Full Year 2024 Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 10.1% versus 8.0% for the prior year; Adjusted EBIT margin* was 16.3% versus 15.1

GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit

Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.

Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor

GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions inno

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, c

Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was $(182) million versus $(136) million Company updates full-year guidance for Organic revenue growth* and Adjusted EBIT margin* GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously

BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00

JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00

Stifel initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00

Goldman initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $87.00

HSBC Securities initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $88.00 from $66.00 previously

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy